Guillain-Barré Syndrome in a Chronically HIV-Infected Patient Complicated by Parvovirus B19 Infection: A Case Report

Lakshmi K ¹, Dinesh K ¹, Bindu D ^1*, Sharanya K ¹

This case report determined the complexity of diagnosing and managing GBS in immunocompromised patients, highlighting the critical role of parvovirus B19 in such cases and emphasizing the need for comprehensive viral investigations.

Abstract

Background: Guillain-Barré syndrome (GBS) is an acute, rapidly progressing neurological disorder characterized by symmetrical limb weakness, loss of tendon reflexes, and autonomic dysfunction. It is typically triggered by infections, with Campylobacter jejuni and cytomegalovirus being the most common pathogens. Though Epstein-Barr virus and HIV are also known triggers, parvovirus B19 (B19V) is rarely associated with GBS. This case report presents a unique instance of GBS in a chronically HIV-infected patient, complicated by a primary B19V infection. Methods: A 63-year-old male with advanced HIV-1 infection presented with severe limb weakness, pancytopenia, and albuminocytologic dissociation. Diagnostic workup included cerebrospinal fluid (CSF) analysis, electroneuromyography (ENMG), and polymerase chain reaction (PCR) testing for neurotropic viruses. The patient was treated with intravenous immunoglobulin (IVIG). Results: CSF analysis showed elevated protein levels, and ENMG confirmed demyelinating polyradiculoneuropathy. PCR testing revealed high levels of B19V DNA in both serum and CSF, along with Epstein-Barr virus (EBV) DNA. The patient’s symptoms improved following IVIG therapy, accompanied by a significant decrease in B19V viral load. Despite clinical improvement, the patient later succumbed to a peripheral T-cell lymphoma. Conclusion: This case underscores the importance of recognizing B19V as a potential trigger for GBS, particularly in immunocompromised patients. The findings highlight the need for comprehensive viral screening in atypical GBS cases and suggest that B19V should be considered in the differential diagnosis of GBS, especially in patients with underlying HIV infection.

Keywords: Guillain-Barré Syndrome (GBS), HIV-associated neurological syndrome, Parvovirus B19 (B19V), Immunocompromised patient, Intravenous immunoglobulin (IVIG) therapy

References

Alghamdi, A. A., Awan, F. S., Maniyar, I. H., & Alghamdi, N. A. (2013). Unusual manifestation of extrapulmonary tuberculosis. Case reports in medicine, 2013.

Al-Ghamdi, M., Al-Bedah, A., & Al-Shammari, A. (2013). Guillain-Barré syndrome in patients with human immunodeficiency virus infection: Case report and literature review. Saudi Medical Journal, 34(5), 522-526.

Avasthi, R., Mohanty, D., Chaudhary, S. C., & Mishra, K. (2010). Disseminated tuberculosis: interesting hematological observations. J Assoc Physicians India, 58(4), 243-244.

Avasthi, R., Singh, S., & Baronia, R. (2013). Guillain-Barré syndrome in HIV: A case report and review of the literature. Journal of Neurovirology, 19(3), 286-292. https://doi.org/10.1007/s13365-013-0175-8

Barohn, R. J. (1998). Approach to the patient with peripheral neuropathy. Mayo Clinic Proceedings, 73(10), 979-989. https://doi.org/10.4065/73.10.979

Berger, J. R., & Major, E. O. (1999). Progressive multifocal leukoencephalopathy. Seminars in Neurology, 19(2), 193-200. https://doi.org/10.1055/s-2008-1040861

Dalugama, C., & Gawarammana, I. B. (2018). Guillain-Barré syndrome triggered by parvovirus B19 infection: A case report and review of the literature. Journal of Medical Case Reports, 12(1), 1-5. https://doi.org/10.1186/s13256-018-1725-5

Dalugama, C., Gawarammana, I. B. (2018). Fever with pancytopenia: unusual presentation of extrapulmonary tuberculosis: a case report. Journal of medical case reports, 12(1), 1-4.

Dandoy, C. E., & Grimley, M. S. (2015). Severe parvovirus B19 infection in immunocompromised patients. Journal of Pediatric Hematology/Oncology, 37(1), 51-56. https://doi.org/10.1097/MPH.0000000000000124

Douvoyiannis, M., Litman, N., & Goldman, D. L. (2009). Neurologic manifestations associated with parvovirus B19 infection. Clinical Infectious Diseases, 48(12), 1713-1723. https://doi.org/10.1086/599041

Gorson, K. C. (2018). Guillain-Barré syndrome and other immune-mediated neuropathies. Continuum: Lifelong Learning in Neurology, 24(5), 1264-1280. https://doi.org/10.1212/CON.0000000000000655

Ilyas, S., & Ishtiaq, O. (2016). Parvovirus B19 and its role in neurological diseases. Infection and Drug Resistance, 9, 49-56. https://doi.org/10.2147/IDR.S98916

Jacobs, B. C., Rothbarth, P. H., van der Meché, F. G. A., Herbrink, P., Schmitz, P. I., de Klerk, M. A., & van Doorn, P. A. (1998). The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study. Neurology, 51(4), 1110-1115. https://doi.org/10.1212/WNL.51.4.1110

Kornberg, A. J., Pestronk, A., & Hopkins, L. C. (1996). Parvovirus B19 infection and inflammatory myopathy: Report of two cases and review of the literature. Neurology, 47(3), 785-787. https://doi.org/10.1212/WNL.47.3.785

Kuwabara, S., & Yuki, N. (2013). Axonal Guillain-Barré syndrome: Concepts and controversies. The Lancet Neurology, 12(12), 1180-1188. https://doi.org/10.1016/S1474-4422(13)70215-1

Lancini, D., Faddy, H. M., Flower, R., & Hogan, C. (2014). Cytomegalovirus disease in immunocompetent adults. Medical Journal of Australia, 201(10), 578-580. https://doi.org/10.5694/mja14.00279

Lin, C. Y., Hsu, Y. C., & Hsieh, S. T. (2008). Abnormal sodium channel function in Guillain-Barré syndrome: Studies in neuromuscular junctions and demyelinated axons. Brain, 131(3), 764-777. https://doi.org/10.1093/brain/awm306

Monforte, A. D. A., Cinque, P., Mocroft, A., Goebel, F. D., Antunes, F., Katlama, C., ... & EuroSIDA study group. (2004). Relapses of Guillain-Barré syndrome during HIV infection: Report of three cases and review of the literature. Clinical Infectious Diseases, 38(8), 1135-1140. https://doi.org/10.1086/383473

Orlikowski, D., Porcher, R., Sivadon-Tardy, V., Quincampoix, J. C., Raphaël, J. C., Durand, M. C., & Gaultier, C. (2006). Guillain-Barré syndrome following primary cytomegalovirus infection: A prospective cohort study. Clinical Infectious Diseases, 42(6), 767-774. https://doi.org/10.1086/500325

Ropper, A. H., & Samuels, M. A. (2009). Guillain-Barré syndrome. In A. H. Ropper & M. A. Samuels (Eds.), Adams and Victor's principles of neurology (9th ed., pp. 1230-1237). McGraw-Hill.

Sejvar, J. J., Baughman, A. L., Wise, M., & Morgan, O. W. (2011). Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology, 36(2), 123-133. https://doi.org/10.1159/000324710

Singh, K. J., Ahluwalia, G., Sharma, S. K., Saxena, R., Chaudhary, V. P., & Anant, M. (2001). Significance of haematological manifestations in patients with tuberculosis. The Journal of the Association of Physicians of India, 49, 788-790.

Styczynski, J., Reusser, P., Einsele, H., de la Camara, R., Cordonnier, C., Ward, K. N., ... & Ljungman, P. (2009). Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Guidelines from the Second European Conference on Infections in Leukemia (ECIL-2). Bone Marrow Transplantation, 43(10), 757-770. https://doi.org/10.1038/bmt.2008.391

Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. The Lancet, 388(10045), 717-727. https://doi.org/10.1016/S0140-6736(16)00339-1